The FDA has approved the use of Veklury, manufactured by Gilead Sciences, for COVID-19 treatment in patients with severe renal impairment. This includes those on dialysis, as they are at high risk for severe COVID-19. The updated prescribing information for Veklury states that dose adjustments and eGFR testing are not required for renal-impaired patients. The approval was based on the REDPINE trials, which showed promising results in reducing hospitalization duration and improving clinical outcomes. Veklury is the only antiviral treatment approved for COVID-19 for use at any stage of renal disease. Gilead Sciences is committed to providing transformational therapies for COVID-19, including for the most vulnerable populations at risk of developing severe disease.

To know more: About the original article click here.